Sun Pharma Advanced Research Company · NSE: SPARC · BSE: 532872
Q4 FY26 results · Jan–Mar 2026
Sun Pharma Advanced Research Company reported revenue from operations of ₹1,853.22 crore (up 6715.8% from Q4 FY25) and net profit of ₹1,761.34 crore for Q4 FY26 (Jan–Mar 2026), on a consolidated basis.
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,853.22 | 27.19 | 68x | 8.45 | 219x |
| Other income | 1.80 | 0.00 | — | 0.00 | — |
| Total income | 1,855.02 | 27.19 | 68x | 8.45 | 220x |
| Profit before tax | 1,760.96 | (60.67) | Turned profit | (80.35) | Turned profit |
| Net profit for the period | 1,761.34 | (59.77) | Turned profit | (80.42) | Turned profit |
| Attributable to shareholders of the company | 1,762.69 | (60.16) | Turned profit | — | — |
| EPS, basic (₹) | 54.27 | (1.84) | Turned profit | (2.48) | Turned profit |
| Net margin (%) | 95.0 | -219.8 | -951.7 |
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,853.22 | 27.19 | 68x | 8.45 | 219x |
| Other income | 1.80 | 0.00 | — | 0.00 | — |
| Total income | 1,855.02 | 27.19 | 68x | 8.45 | 220x |
| Profit before tax | 1,760.70 | (60.98) | Turned profit | (80.57) | Turned profit |
| Net profit for the period | 1,760.70 | (60.98) | Turned profit | (80.57) | Turned profit |
| EPS, basic (₹) | 54.26 | (1.88) | Turned profit | (2.48) | Turned profit |
| Net margin (%) | 95.0 | -224.3 | -953.5 |
Consolidated
- Filed with BSE
- 18 May 2026, 20:58 IST
- Board meeting
- 18 May 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 18 May 2026, 20:58 IST
- Board meeting
- 18 May 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Audited
- Source
- XBRL filing on BSE